Breast Cancer Clinical Research

The oncology unit at Lux Med Onkologia conducts studies on HR+/HER2‑negative breast cancer, aiming to test novel endocrine‑based combinations and improve survival outcomes.

  • Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With HR+/HER2‑ Metastatic Breast Cancer Who Have Received Endocrine Therapy
  • A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants with Early Breast Cancer (EMBER‑4)

The trials emphasize response rates and adjuvant therapy effectiveness to reduce recurrence risk.

Renal Cell Carcinoma Trials

Researchers explore clear cell and non‑clear cell renal cell carcinoma to assess immunotherapy and targeted drug combinations for better disease control.

  • An Open‑label, Randomized Phase 3 Study of Immune and Targeted Combination Therapies, as First‑line Treatment in Participants with Advanced clear cell renal cell carcinoma (ccRCC)
  • Pembrolizumab + Lenvatinib for First Line Non‑Clear Cell, Renal Cell Carcinoma

The goal is to improve progression‑free survival and overall response in patients with advanced kidney cancer.

Bladder Cancer Investigation

The department evaluates peri‑operative immunotherapy for cis‑eligible muscle‑invasive bladder cancer, comparing pembrolizumab‑based regimens with standard chemotherapy.

  • A global study to evaluate peri‑operative pembrolizumab with chemotherapy versus placebo to pembrolizumab plus chemotherapy in cisplatin eligible patients.

Primary endpoints include event‑free survival following radical cystectomy and lymph node dissection.

Metastatic Castration‑Resistant Prostate Cancer

Studies target metastatic castration‑resistant prostate cancer by testing novel checkpoint inhibitors combined with chemotherapy to extend radiographic progression‑free survival.

  • A Study of Lorikerlimab with Docetaxel or Docetaxel Alone in Participants with Metastatic Castration‑Resistant Prostate Cancer

The research aims to determine whether immune‑based therapy offers a benefit over standard docetaxel treatment.

MSI‑High Metastatic Colorectal Cancer

Trials focus on MSI‑High or dMMR stage IV colorectal cancer, assessing multi‑arm immunotherapy combinations to increase objective response rates.

  • A Multi Arm Study in Participants with MSI‑High Metastatic Colorectal Cancer

The objective is to identify the most effective regimen among several investigational agents.